Arkolith/Insider Trading/KPTI/Form 4

Poulton Stuart

EVP, Chief Development OfficerKaryopharm Therapeutics Inc. (KPTI) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$48K
Net Open-Market Flow
-$48K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)5K$9.41$48K94K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001942597-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML